Hyperfibrinogenemia and functional outcome from acute ischemic stroke

Stroke

Volumn 40, Issue 5, 2009, Pages 1687-1691

  Del Zoppo, Gregory J ^a   Levy, David E ^c   Wasiewski, Warren W ^c   Pancioli, Arthur M ^f   Demchuk, Andrew M ^h   Trammel, James ^b   Demaerschalk, Bart M ^d   Kaste, Markku ^e   Albers, Gregory W ^g   Ringelstein, Eric B ⁱ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Statprobe   (United States)

^c Neurobiological Technologies Inc   (United States)

^d MAYO CLINIC HOSPITAL   (United States)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Acute ischemic stroke; Defibrinogenation; Fibrinogen; Functional outcome

Indexed keywords

FIBRINOGEN; PLACEBO;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME; ACUTE DISEASE; BRAIN HEMORRHAGE; DISABILITY; FACTORIAL ANALYSIS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SURVIVAL;

ACUTE DISEASE; AGED; CEREBRAL HEMORRHAGE; DISABILITY EVALUATION; FACTOR ANALYSIS, STATISTICAL; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; STROKE; SURVIVAL; TREATMENT OUTCOME;

EID: 65549096662     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.527804     Document Type: Article

References (24)

1. Di Napoli M, Papa F. Should neurologists measure fibrinogen concentrations? J Neurol Sci. 2006;246:5-9.
2. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
3. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Fra-mingham Study. Am Heart J. 1987;113:1006-1010.
4. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol. 1992;2:457-466.
5. Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J. 1993;69:338-342.
6. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ. 1991;303:605-609.
7. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
8. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wil-helmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lew-ington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799-1809.
9. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA. 2000;283:2395-2403.
10. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM; for the ESTAT investigators. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet. 2006;368:1871-1878.
11. Clauss A. [Rapid physiological coagulation method in determination of fibrinogen.]. Acta Haematol. 1957;17:237-246.
12. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989.
13. P Version 8. SAS Institute Inc, Cary, NC; 1999-2001.
14. Ng KFJ, Lam CCK, Chan LC. In vivo effect of haemodilution with saline on coagluation: a randomized controlled trial. Brit J Anaesth. 2002;88: 475-480.
15. Ruttmann TG. Haemodilution enhances coagulation (edit). Brit J Anaesth. 2002;88:470-472.
16. Turaj W, Slowik A, Dziedzic T, Pulyk R, Adamski M, Strojny J, Szczudlik A. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci. 2006;246: 13-19.
17. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001; 32:133-138.
18. Di Napoli M, Papa F; for the Villa Pina Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke. 2002;33:1763-1771.
19. Lip GY, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis. 2002;13:339-347.
20. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35: 2300-2305.
21. Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR, for the NINDS rtPA Stroke Study Group. Hemostatic activation and outcome after recom-binant tissue plasminogen activator therapy for acute ischemic stroke. Stroke. 2006;37:1798-1804.
22. Tamam Y, Iltumur K, Apak I. Assessment of acute phase proteins in acute ischemic stroke. Tohoku J Exp Med. 2005;206:91-98.
23. Collet JP, Soria J, Mirshahi M, Hirsch M, Dagonnet FB, Caen J, Soria C. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood. 1993;82:2462-2469.
24. Gonzaelez-Conejero R, Fernandez-Cadenas I, Iniesta JA, Marti-Fabregas J, Obach V, Alvarez-Sabin J, Vicente V, Corral J, Montaner J; Proyecto Ictus Research Group. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke. 2006; 37:2288-2293.